NASDAQ:GRTS Gritstone bio - GRTS Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Gritstone bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $2.63 -0.02 (-0.75%) (As of 03/22/2023 11:59 AM ET) Add Compare Share Share Today's Range$2.59▼$2.7550-Day Range$2.13▼$3.5652-Week Range$1.71▼$5.85Volume161,960 shsAverage Volume784,134 shsMarket Capitalization$230.55 millionP/E RatioN/ADividend YieldN/APrice Target$5.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Gritstone bio MarketRank™ ForecastAnalyst RatingHold2.33 Rating ScoreUpside/Downside86.6% Upside$5.00 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews Sentiment0.64Based on 8 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.26) to ($1.24) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.84 out of 5 starsMedical Sector710th out of 983 stocksBiological Products, Except Diagnostic Industry127th out of 163 stocks 3.2 Analyst's Opinion Consensus RatingGritstone bio has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 2 buy ratings, no hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $5.00, Gritstone bio has a forecasted upside of 86.6% from its current price of $2.68.Amount of Analyst CoverageGritstone bio has only been the subject of 1 research reports in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for GRTS. Previous Next 0.0 Dividend Strength Dividend YieldGritstone bio does not currently pay a dividend.Dividend GrowthGritstone bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for GRTS. Previous Next 3.1 News and Social Media Coverage News SentimentGritstone bio has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.34 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Gritstone bio this week, compared to 1 article on an average week.Search Interest6 people have searched for GRTS on MarketBeat in the last 30 days. This is an increase of 20% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Gritstone bio to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Gritstone bio insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.47% of the stock of Gritstone bio is held by insiders.Percentage Held by Institutions48.06% of the stock of Gritstone bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Gritstone bio are expected to grow in the coming year, from ($1.26) to ($1.24) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Gritstone bio is -2.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Gritstone bio is -2.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGritstone bio has a P/B Ratio of 1.31. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Gritstone bio (NASDAQ:GRTS) StockGritstone bio, Inc. clinical-stage biotechnology company, which engages in developing the next generation of cancer immunotherapies to fight multiple cancer types. The company was founded by Andrew Allen, Timothy Chan, Mark Cobbold, Graham Lord, Naiyer Rizvi and Jean-Charles Soria in August 2015 and is headquartered in Emeryville, CA.Read More Receive GRTS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Gritstone bio and its competitors with MarketBeat's FREE daily newsletter. Email Address GRTS Stock News HeadlinesMarch 17, 2023 | benzinga.comGritstone Bio Stock (NASDAQ:GRTS), Short Interest ReportMarch 17, 2023 | americanbankingnews.comGritstone bio, Inc. (NASDAQ:GRTS) to Post FY2027 Earnings of ($0.03) Per Share, HC Wainwright ForecastsMarch 22, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.March 16, 2023 | americanbankingnews.comGritstone bio, Inc. (NASDAQ:GRTS) Expected to Post Q1 2023 Earnings of ($0.38) Per ShareMarch 15, 2023 | finance.yahoo.comGritstone bio Announces Presentations on Neoantigen Prediction Capabilities and Cancer Vaccine Programs at the 2023 AACR Annual MeetingMarch 15, 2023 | americanbankingnews.comGritstone bio (NASDAQ:GRTS) Earns "Buy" Rating from HC WainwrightMarch 13, 2023 | finance.yahoo.comGritstone bio, Inc. (NASDAQ:GRTS) Q4 2022 Earnings Call TranscriptMarch 11, 2023 | seekingalpha.comGritstone bio Inc. (GRTS) Q4 2022 Results - Earnings Call TranscriptMarch 22, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.March 11, 2023 | finance.yahoo.comGritstone bio Full Year 2022 Earnings: Beats ExpectationsMarch 9, 2023 | finance.yahoo.comGritstone bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate UpdatesMarch 2, 2023 | finance.yahoo.comGritstone bio to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update on March 9, 2023February 27, 2023 | finance.yahoo.comGritstone bio to Participate in 43rd Annual Cowen Healthcare ConferenceFebruary 14, 2023 | finance.yahoo.comGritstone bio and the National Cancer Institute (NCI) Establish a Clinical Trial Agreement to Evaluate a Neoantigen Cell Therapy-Vaccine CombinationFebruary 13, 2023 | msn.comUAL, GRTS and VRNT are among after hour moversJanuary 25, 2023 | finance.yahoo.comInvestors in Gritstone bio (NASDAQ:GRTS) have unfortunately lost 66% over the last three yearsJanuary 24, 2023 | finance.yahoo.comGritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)January 22, 2023 | seekingalpha.comGritstone bio (GRTS) Presents at the 41st Annual J.P. Morgan Healthcare Conference - SlideshowJanuary 18, 2023 | finance.yahoo.comGritstone bio to Participate in Upcoming Investor ConferencesJanuary 2, 2023 | seekingalpha.comGritstone bio: Keep An Eye On This Discounted Cancer Vaccine Developer In 2023December 15, 2022 | finance.yahoo.comGritstone bio to Present at 41st Annual J.P. Morgan Healthcare ConferenceDecember 13, 2022 | msn.comPositive Moderna, Merck cancer vaccine data advances mRNA promise, shares riseDecember 13, 2022 | marketwatch.comGritstone Shares Jump Over 14% on mRNA Patent NewsDecember 13, 2022 | msn.comGritstone bio rallies after U.S. patent win for mRNA-based vaccine techDecember 13, 2022 | finance.yahoo.comGritstone bio Granted Two New U.S. Patents for Self-amplifying mRNA (samRNA)December 5, 2022 | finance.yahoo.comPredictive Oncology Appoints Leading Biopharma Executive Matthew J. Hawryluk Ph.D. to the Board of DirectorsDecember 5, 2022 | finance.yahoo.comPredictive Oncology Appoints Leading Biopharma Executive Matthew J. Hawryluk Ph.D. to the Board of DirectorsSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive GRTS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Gritstone bio and its competitors with MarketBeat's FREE daily newsletter. Email Address GRTS Company Calendar Last Earnings11/02/2021Today3/22/2023Next Earnings (Estimated)5/04/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:GRTS CUSIPN/A CIK1656634 Webwww.gritstoneoncology.com Phone(510) 871-6100FaxN/AEmployees193Year FoundedN/APrice Target and Rating Average Stock Price Forecast$5.00 High Stock Price Forecast$7.00 Low Stock Price Forecast$2.00 Forecasted Upside/Downside+90.1%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.33) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-119,690,000.00 Net Margins-600.09% Pretax Margin-600.09% Return on Equity-72.52% Return on Assets-52.99% Debt Debt-to-Equity Ratio0.11 Current Ratio5.26 Quick Ratio5.25 Sales & Book Value Annual Sales$19.94 million Price / Sales11.56 Cash FlowN/A Price / Cash FlowN/A Book Value$2.05 per share Price / Book1.28Miscellaneous Outstanding Shares87,660,000Free Float83,744,000Market Cap$230.55 million OptionableNot Optionable Beta0.52 Key ExecutivesAndrew R. AllenPresident, Chief Executive Officer & DirectorErin E. JonesChief Operating Officer & Executive Vice PresidentVassiliki Celia EconomidesChief Financial Officer & Executive Vice PresidentKarin JoossExecutive VP & Head-Research & DevelopmentMatthew J. HawrylukChief Business Officer & Executive Vice PresidentKey CompetitorsFennec PharmaceuticalsNASDAQ:FENCCabaletta BioNASDAQ:CABAC4 TherapeuticsNASDAQ:CCCCMolecular PartnersNASDAQ:MOLNCentury TherapeuticsNASDAQ:IPSCView All CompetitorsInstitutional OwnershipJane Street Group LLCBought 13,890 shares on 2/15/2023Ownership: 0.082%Susquehanna Fundamental Investments LLCBought 30,547 shares on 2/15/2023Ownership: 0.037%Virtu Financial LLCSold 22,438 shares on 2/15/2023Ownership: 0.035%Boothbay Fund Management LLCBought 28,110 shares on 2/15/2023Ownership: 0.034%Shay Capital LLCBought 12,494 shares on 2/15/2023Ownership: 0.015%View All Institutional Transactions GRTS Stock - Frequently Asked Questions Should I buy or sell Gritstone bio stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gritstone bio in the last year. There are currently 1 sell rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" GRTS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GRTS, but not buy additional shares or sell existing shares. View GRTS analyst ratings or view top-rated stocks. What is Gritstone bio's stock price forecast for 2023? 3 Wall Street analysts have issued twelve-month price targets for Gritstone bio's shares. Their GRTS share price forecasts range from $2.00 to $7.00. On average, they anticipate the company's share price to reach $5.00 in the next twelve months. This suggests a possible upside of 90.1% from the stock's current price. View analysts price targets for GRTS or view top-rated stocks among Wall Street analysts. How have GRTS shares performed in 2023? Gritstone bio's stock was trading at $3.45 at the start of the year. Since then, GRTS shares have decreased by 23.8% and is now trading at $2.63. View the best growth stocks for 2023 here. When is Gritstone bio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023. View our GRTS earnings forecast. How were Gritstone bio's earnings last quarter? Gritstone bio, Inc. (NASDAQ:GRTS) issued its quarterly earnings results on Tuesday, November, 2nd. The company reported ($0.36) earnings per share for the quarter, topping analysts' consensus estimates of ($0.52) by $0.16. The business had revenue of $2.61 million for the quarter, compared to the consensus estimate of $3 million. Gritstone bio had a negative trailing twelve-month return on equity of 72.52% and a negative net margin of 600.09%. What ETFs hold Gritstone bio's stock? ETFs with the largest weight of Gritstone bio (NASDAQ:GRTS) stock in their portfolio include Direxion mRNA ETF (MSGR) and ETFMG Treatments Testing and Advancements ETF (GERM).ALPS Medical Breakthroughs ETF (SBIO). What is Andrew Allen's approval rating as Gritstone bio's CEO? 1 employees have rated Gritstone bio Chief Executive Officer Andrew Allen on Glassdoor.com. Andrew Allen has an approval rating of 100% among the company's employees. This puts Andrew Allen in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Gritstone bio own? Based on aggregate information from My MarketBeat watchlists, some companies that other Gritstone bio investors own include ADMA Biologics (ADMA), Bionano Genomics (BNGO), Matinas BioPharma (MTNB), Novan (NOVN), Sorrento Therapeutics (SRNE), Zosano Pharma (ZSAN), Enerplus (ERF), Oncolytics Biotech (ONCY), SCYNEXIS (SCYX) and CBL & Associates Properties (CBL). When did Gritstone bio IPO? (GRTS) raised $85 million in an IPO on Friday, September 28th 2018. The company issued 6,100,000 shares at $13.00-$15.00 per share. Goldman Sachs, Cowen and Barclays acted as the underwriters for the IPO and BTIG was co-manager. What is Gritstone bio's stock symbol? Gritstone bio trades on the NASDAQ under the ticker symbol "GRTS." Who are Gritstone bio's major shareholders? Gritstone bio's stock is owned by a variety of retail and institutional investors. Top institutional investors include Point72 Asset Management L.P. (9.21%), Frazier Life Sciences Management L.P. (6.19%), Morgan Stanley (2.39%), Assenagon Asset Management S.A. (2.33%), Artal Group S.A. (2.23%) and Geode Capital Management LLC (0.85%). Insiders that own company stock include Erin Jones and Raphael Rousseau. View institutional ownership trends. How do I buy shares of Gritstone bio? Shares of GRTS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Gritstone bio's stock price today? One share of GRTS stock can currently be purchased for approximately $2.63. How much money does Gritstone bio make? Gritstone bio (NASDAQ:GRTS) has a market capitalization of $230.55 million and generates $19.94 million in revenue each year. The company earns $-119,690,000.00 in net income (profit) each year or ($1.33) on an earnings per share basis. How many employees does Gritstone bio have? The company employs 193 workers across the globe. How can I contact Gritstone bio? Gritstone bio's mailing address is 5858 HORTON STREET SUITE 210, EMERYVILLE CA, 94608. The official website for the company is www.gritstoneoncology.com. The company can be reached via phone at (510) 871-6100 or via email at ir@gritstone.com. This page (NASDAQ:GRTS) was last updated on 3/22/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.